An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC) An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants wit ...
An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC) An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants wit ...